Medtronic stock gets $110 target at TD Cowen on FDA clearance
TD Cowen reiterated a Buy rating and $110 price target for Medtronic (NYSE:MDT) after FDA clearance of its Hugo system for general surgery, expanding its U.S. market. The stock, currently at $102.88, has risen 37% in six months. Piper Sandler also upgraded MDT to Overweight, citing growth drivers. Medtronic announced a prospectus correction for its MiniMed exchange offer.
How this was made
The 30-second read
Why it matters
The FDA clearance expands Hugo’s U.S. indications by about 3.5 million additional procedures annually, which TD Cowen says materially increases the addressable market and supports further adoption.
Market read
Traders may reassess MDT’s growth outlook and valuation sensitivity to regulatory-driven indication expansion, reinforced by a reiterated Buy and unchanged price target.
What to watch
No details are provided on reimbursement, competitive dynamics in general surgery, or how quickly adoption ramps after clearance, which could temper near-term expectations.
Background
Medtronic’s Hugo robotic surgery platform previously had FDA clearance for urological procedures; TD Cowen highlights new general surgery clearance.
Ticker impact
TD Cowen reiterates Buy after Medtronic announced FDA clearance of its Hugo system for general surgery, expanding U.S. indications by ~3.5M procedures annually.
Likely upward bias as the market prices in expanded indications and sustained analyst confidence around MDT’s robotic surgery growth.
The article ties the FDA clearance directly to a larger U.S. procedure opportunity and frames TD Cowen’s unchanged Buy/PT as a response to that incremental regulatory milestone.
Market effects
Positive read-through for medical device peers tied to robotic-assisted surgery adoption and FDA-driven indication expansion.
Primarily U.S. healthcare device demand expectations given the clearance expands U.S. procedures.
Limited direct global impact in the text, but could support broader investor sentiment toward medtech innovation and regulatory progress.
Counterpoint
The article is largely an analyst reiteration; the incremental commercial impact of the new indications may take time to translate into revenue.
Key entities
- companyMedtronic, Inc.
Medical device maker whose Hugo system received FDA clearance for general surgery, expanding indications.
- analyst_firmTD Cowen
Reiterated Buy rating and $110 price target following the FDA clearance.
- productHugo (robotic surgery system)
Medtronic platform whose FDA indications expanded from urology to general surgery.


